Modernizing Mental Health Through Innovative Technology & Psychedelics

Mydecine Innovations Group Inc. (CNSX: MYCO) (OTCMKTS: MYCOF) (FSE:0NF) and its subsidiary MindLeap Health have built an advanced digital health platform that helps people connect with mental health specialists that can empower them to thrive and develop habits for a healthy mind.

MINDLEAP HEALTH

An Advanced Digital Health Platform

MindLeap supports people looking to achieve personal transformations and overcome mental health challenges—it's the only platform the combines Telehealth and tracking.

Health & Recovery Coaching

Assist people in translating psychedelic experiences into positive changes that overcome addiction.

Track Your Mental Health

Track your mood, emotions, habits and progress towards improved well-being over time.

Investment Highlights

Massive Market Size

More than 300 million people suffer from depression worldwide, while the telemedicine market is estimated to be worth upwards of $30 billion—growing at a ~20% CAGR through 2025.

Near-term Launch

MindLeap's software platform was designed by leading psychologists and neuroscientists and is set to launch in the third quarter of 2020, providing a near-term catalyst for investors.

Mydecine Acquisition

Mydecine Innovations Group Inc. acquired 100% interest in MindLeap's Digital Telehealth Platform focused on the emerging psychedelics industry, to unlock synergies between the two companies.

Additional Mydecine Subsidiaries

NeuroPharm Inc.

NeuroPharm Inc. (NPI) is developing a unique and proprietary set of pharmaceutical and natural health products addressing mental wellness in vulnerable populations.

Mydecine Health Sciences

Mydecine Health Sciences (MHS) is a vertically integrated company developing novel fungtional© mushroom products and psychedelic medicines for healthy and vulnerable populations.

BECOME AN INVESTOR

Download the Investor Presentation

Copyright © 2020. All rights reserved.